DLG5 and breast carcinoma: Loss of DLG5 in breast cancer cells inhibited the Hippo pathway by decreasing the phosphorylation of MST1/2, LATS1 (two activators of YAP/TAZ) and by increasing the nuclear localization of YAP, the loss of DLG5 induced the transcription of TEAD-target genes and, through this mechanism, promoted tumor cell proliferation [399].